By Elric Langton | 11th November 2021
One of the great hopes for treating COVID-19, Synairgen, gave investors a boost in confidence with news the respiratory drug specialist confirmed it was starting a Phase III study. The company also said it had met its recruitment target of 610 randomised people for the study, evaluating its investigational drug SNG00β¦